Category Events

The days of partnership R&D in health.   https://www.afssi-connexions.fr/

Dive into Antibody next generation with NanoMedSyn technology. https://informaconnect.com/antibody-engineering-europe/

NanoMedSyn develops an application of its vectors on therapeutic antibodies and probes that the addition of AMFA (=M6Pn) does not alter antigen recognition or FcRn recycling. The article is published by Journal of Controlled Release. J Control Release 2023, 358:465-475.

NanoMedSyn will participate to the International Symposium on Inorganic  and Environmental Materials ISIEM2023 in Montpellier, France. The symposium will focus on the newest research and technologies on inorganic materials : Nanomaterials, Biomaterials, Functional Materials… https://isiem2023.sciencesconf.org

Join us at Paris Saclay B2B on June, the 1st and 2nd. https://paris-saclay-spring.com/programme-paris-saclay-spring/

We will be present at BIO-Europe Spring for one-to-one meeting. https://informaconnect.com/bioeurope-spring/

The 3rd Immune-Oncology World Congress Immuno-Oncology2022 will focus on the latest developments and findings in immuno-oncology therapy as well as targeted therapy. The Congress will examine treatments available on the market as well as treatments still in the development stage. A poster of our work will be on display for the duration of the Congress.  

Immunology, looking to the future of medical sciences. The Thematic Meeting: « Immunology, looking to the future of medical sciences » is a major event for the immunology sector in the south of France. http://fr.ap-hm.fr/sites/default/files/files/221011_%20Programme%20-%20%20Immunology,%20looking%20to%20the%20future%20of%20medical%20science.pdf

Day of the cluster : Biotherapy Innovation Occitanie October 13, 2022 in Montpellier https://www.agence-adocc.com/biotherapie-innovation-occitanie/  

NanoMedSyn is co-organiser of  the 2nd Symposium on delivery and target for pediatric tumors, on 23-24th June in Switzerland (Schwarzsee). Our collaborative work and of the company have been presented.